NOTICE: Exciting changes are coming to the National Forensic Laboratory Information System program. From a technology standpoint there should be no negative impact to you, our users, and you can upload your data as you normally would; however, as with any transition, there may be some delays and bumps along the way. We ask for your patience and understanding as we navigate these waters. As always, if you have any questions, concerns, or needs, please reach out to us at NFLIS@dea.gov. Thank you for your patience and support, Your NFLIS Team.
NFLIS News
NFLIS-Drug Snapshot (September 2023)
Nine new substances that were reported across the West, Midwest, South, and Northeast between July 1, 2023 and September 30, 2023, are highlighted in this snapshot. Get the snapshot.
NFLIS-Drug Brief: Substances Co-Reported with Fentanyl in NFLIS-Drug and DEA-Tox, January 2013-June 2023
- Fentanyl has been one of the top five drugs reported to NFLIS-Drug every year since 2017.
- From January to June 2023, 26% of items reported to contain fentanyl also contained at least one co-reported substance.
- In recent years, heroin, xylazine, and fentanyl-related compounds have been the substances most frequently co-reported with fentanyl.
2022 Medical Examiner and Coroner Survey Report
During calendar year 2021, 1,440,580 death cases were referred to the 1,606 medical examiner and coroner offices responding the NFLIS-MEC survey. Get the report.
NFLIS-Drug 2022 Annual Report
From 2021 to 2022, national reports of fentanyl, cocaine, fluorofentanyl, and psilocin/psilocybin increased significantly, while national reports of methamphetamine, cannabis/THC, heroin, alprazolam, and buprenorphine decreased significantly.
NFLIS-DRUG 2022 Midyear Report
At the national level, fluorofentanyl reports nearly doubled from 6,509 reports in the first half of 2021 to 12,174 reports in the first half of 2022. Get the report.
2022 Synth-Opioids Annual Report
The NFLIS DEA Synth-Opioids welcomed 184 new members and 28 forum topics in 2022. Get the report.
2021 Toxicology Laboratory Survey Report
Among responding toxicology laboratories, 48% used a reference laboratory, 29% served as a reference laboratory, and 23% responded that they did not use or serve as a reference laboratory for toxicology testing. Get the report.
NFLIS-Drug Special Report: Gabapentin and Pregabalin Reported in NFLIS, 2011–2020
Gabapentin and pregabalin are prescription drugs that have been approved by the U.S. Food and Drug Administration. From 2011 to 2019, estimated annual gabapentin and pregabalin reports in NFLIS-Drug increased 242% and 18%, respectively. From 2019 to 2020, gabapentin and pregabalin reports decreased 7% and 28%, respectively.